+ hematopoietic stem cells into dendritic cells (DCs) 
Introduction
Recently, significant improvements have been made regarding the development and utilization of retroviral and lentiviral vectors. [1] [2] [3] [4] In particular, the use of these vectors for the genetic modification of dendritic cells has become of interest, because these cells are widely used for clinical protocols in the immunotherapy of cancer. DCs are the most potent antigen-presenting cell type for the priming of naïve, and the activation of resting T lymphocytes. They can be used to efficiently present peptides which are derived from tumor-associated antigens (TAAs). [5] [6] [7] [8] [9] [10] Primary activation of tumor-specific cytotoxic T cells has been achieved by loading DCs with recombinant protein, tumor-derived peptides, transfer of mRNA or viral DNA coding for TAAs. [11] [12] [13] [14] [15] [16] [17] [18] [19] Also vaccination with dendritic cell-derived exosomes and fusion of DCs with carcinoma cells has been shown to elicit an anti-tumor response. 20, 21 The advantage of viral expression is seen in the activation of a broad spectrum of T cells with differ-
typed Moloney murine leukemia virus (MoMuLV) particles using 100-150 multiplicity of infection. During expansion of transduced cells with immature phenotype, transgene expression was strongly silenced, but upon differentiation into mature DCs, residual transgene expression was retained. Intracellular processing of the provirally expressed tyrosinase was tested in a chromium release assay utilizing a cytotoxic T cell clone specific for a HLA-A * 0201-restricted tyrosinase peptide. We suggest that retroviral transduction of tumor-associated antigens in hematopoietic progenitor cells and subsequent differentiation into DCs is a suitable basis for the development of potent anti-tumor vaccines.
Gene Therapy (2002) 9, 1551-1560. doi:10.1038/sj.gt.3301821 ent T cell receptor (TCR) specificities against various peptides. Furthermore, the direct modification of dendritic cells or DC progenitors has advantages over transiently RNA-transfected or antigen-pulsed DCs, including stable expression of a transgene and high in vitro expansion potential for multiple reinfusions. The most challenging aspects in the development of a successful immunotherapy utilizing DCs are the gene transfer, long-term expression, efficient processing and presentation of the chosen tumor-associated antigen. In this study, we developed an efficient protocol for the maintainance and expansion of CD34 + umbilical cord blood cells and transduced these cells with VSV-G pseudotyped Moloney murine leukaemia virus. In order to determine the efficacy of transduction and the proviral expression we used a retroviral vector coding for a bicistronic human tyrosinase-EGFP-ZEO R and as a control a vector coding for EGFP-ZEO R . Intracellular processing and presentation of the provirally expressed tyrosinase antigens was confirmed by a cytotoxicity assay utilizing a HLA-A * 0201-restricted T cell clone reactive to a tyrosinase-derived peptide. In addition, the transductions with a high multiplicity of infection provided stable expression of the proviral coded proteins until senescence of the CD34 + -derived DCs.
Results

Efficient transduction of human umbilical cord blood CD34
+ cells with VSV-G pseudotyped Moloney murine leukemia particles coding for human tyrosinase and EGFP MoMuLV-derived vectors require cell division for efficient transduction of target cells. Primary umbilical cord blood cells are mostly quiescent and must therefore be expanded for efficient retroviral transduction. After preparation of the cells, they were expanded in a stem cell medium containing appropriate cytokines as described in Materials and methods. In order to estimate the optimal time point for transduction, cell numbers of the cultures were determined every day. The CD34 + cells began to proliferate at days 3 to 5 after isolation and a maximal proliferation of the cells was seen on days 5 to 10. Non-transduced cells and transduced cells from all preparations expanded 107-to 204-fold (164.1 ± 44.7) during a 10-day in vitro culture ( Figure 1 ). Helper free Moloney murine leukemia virus vectors expressing EGFP-Zeo R fusion protein or a bicistronic human tyrosinase-IRES-EGFP-Zeo R were made by cotransfection of 293T cells with packaging plasmids and retroviral vector driven by the cytomegalovirus (CMV) promoter. The transient packaging system provided a retroviral titer ranging from 1.0 to 1.2 × 10 7 and 0.6 to 3.6 × 10 7 IU/ml for particles encoding for pcz-CFG5-IEGZ and pcz-CFG5-Tyr-IEGZ, respectively. CD34
+ cells in the phase of maximal proliferation on days 5 to 6 were transduced with viral supernatants representing a 100 to 150 multiplicity of infection (MOI). This high number of VSV-G pseudotyped particles had no obvious effect on the proliferation rate or on the viability of the CD34 + cells, as determined by trypan blue exclusion. EGFP marker gene expression was assayed 72 h after transduction. We found an average transduction efficacy of 50% for pcz-CFG5-IEGZ, and of 45% for the pcz-CFG5-Tyr-IEGZ, respectively as determined by FACS analysis of proviral EGFP expression. With our transduction protocol we were able to transduce up to 80% of the CD34 + target cells ( Figure  2a) . Although the mean fluorescence of transduced cells was low, EGFP expressing cells could clearly be identified (Figure 2b) .
To estimate the copy number of the provirus in the genomes of the hematopoietic stem cells, we performed transductions of cells at 100 MOI. The proviral copy number of the provirus in the cell culture well, transduced with the pcz-CFG5-Tyr-IEGZ vector, was calculated by using the endogenous tyrosinase allele as calibration standard (two tyrosinase copies per genome) ( Figure 3 ). As expected, we did not detect proviral DNA coding for tyrosinase in the non-transduced cells, but could clearly demonstrate multiple proviral copies in the cells transduced with pcz-CFG5-Tyr-IEGZ. The calculated relative proviral copy number of the CD34 + cells emitting EGFP fluorescence was approximately 10-12 copies per transduced cell.
Maturation of CD34
+ cells into dendritic cells with stable expression of the proviral proteins From day 10 onwards, the CD34 + cells began to attach in the cell culture and upon stimulation with a higher dose of TNF-␣ (50 ng/ml) the cells lost their immature phenotype as shown by the down-regulation of the CD34 surface marker, and they differentiated into DCs with the characteristic high expression of HLA-DR, CD11c, CD80, CD83, CD86 and CD40, whereas surface marker characteristics for other cell types (CD3, T cells; CD19, B cells, data not shown) were either missing or only slightly expressed. E-cadherin expression which is characteristic for Langerhans cells was not detected in differentiated DCs (Figure 4 ). In summary, no obvious difference in the expression of DC characteristic surface proteins was found between EGFP-negative and EGFP-positive CD34 + -derived DCs in the same culture. In addition, we did not find obvious differences in the expression of surface markers when comparing transduced cells with mock transduced DCs (data not shown). A decline in the percentage of cells positive for EGFP expression was observed among proliferating cells (Figure 5a ). The mean fluorescence intensity of EGFP + cells, relative to the non-transduced (EGFP Ϫ ) cells, remained stable over time ( Figure  5b ). Both developed a higher autofluorescence upon differentiation into DCs. As seen in Figure 5b , the EGFP mean fluorescence intensity of the bicistronic expressed tyrosinase-IRES-EGFP-ZEO R on day 3 after transduction was about 160 mean fluorescence intensity with a signalto-noise ratio (mean of fluorescence intensity of EGFP + cells divided by the mean of fluorescence intensity of EGFP Ϫ cells) between 10 to 12. This signal-to-noise ratio was stable throughout the whole cell cultivation. The low mean fluorescence data obtained with the retroviral vector is probably due to diminished fluorescence activity caused by the EGFP-Zeo R fusion product, because cells transduced with a retroviral vector coding for EGFP showed an increased (40-fold) mean fluorescence when compared with pcz-CFG5-Tyr-IEGZ-transduced cells (data not shown). Furthermore, we found that upon differentiation into the DC-phenotype beginning with day 10, cell proliferation stopped, yet the percentage of EGFPGene Therapy positive cells now remained stable until cells underwent senescence, which was seen 6 to 7 weeks after transduction (data not shown).
To further verify, that the expression of the transgenes became stable in differentiated DCs over the in vitro cultivation time, we performed a real-time PCR of a 207 bp region of tyrosinase exon1 (data not shown). We titrated an external standard calibration by using the vector pcz-CFG5-Tyr-IEGZ. We included non-transduced CD34 + in the experiment and found no endogenous expression of the gene. Proviral tyrosinase transcripts were found at all time-points analyzed in transduced DCs as calculated by second derivative analysis method. 22 The expression level of tyrosinase mRNA at day 3 after transduction was set at 100%. The expression level decreased to 1.8% on day 8 post transduction (dpt), but remained stable at all other time-points (15 dpt: 1.8%; 19 dpt: 3.5%; 23 dpt: 3.7%), suggesting stable expression of the transgene in differentiated DCs. Therefore, silencing of the proviral DNA was most prominent during the proliferation phase of nondifferentiated stem cells. However, residual tyrosinase expression was stable in differentiated DCs.
Expression of ectopic tyrosinase protein in transduced CD34
+ derived dendritic cells To confirm the expression of the tyrosinase protein in transduced CD34
+ -derived DCs, we used our newly developed 9A1 monoclonal antibody. We validated the feasibility of our antibody by staining pt67 cell lines permanently expressing pcz-CFG5-IEGZ (pt67-IEGZ) and pcz-CFG5-Tyr-IEGZ (pt67-Tyr-IEGZ), respectively. As seen in Figure 6a 
CD34
+ -derived dendritic cells express and present proviral tyrosinase leading to activation of specific cytotoxic T cells
To assay whether CD34 + -derived DCs are capable of expressing, processing and presenting the tyrosinase coded by the provirus, we determined their capacity to induce the cytotoxic activity of the tyrosinase peptidespecific T cell clone TyrF8. 23 This clone specifically recognizes the peptide YMDGTMSQV which is bound by HLA-A * 0201 molecules. 23 As shown in Figure 7 , CD34 + -derived DCs from two donors with proviral expression of tyrosinase were efficiently lysed by the tyrosinase peptide-specific T cell clone, suggesting that the provirally expressed tyrosinase was intracellularly processed and presented through MHC I molecules. In contrast, CD34 + -derived DCs transduced with the control vector pcz-CFG5-IEGZ and differentiated into DCs were not lysed. It is noteworthy, that we did not find any difference in TyrF8-mediated cytotoxicity when unloaded DCs were compared with pcz-CFG5-IEGZ transduced CD34 + -derived DCs. We conclude that the transduction procedure did not influence the viability of the cells nor the outcome of the cytotoxicity assay.
Discussion
The in vitro genetic manipulation of DCs for the expression of tumor-associated antigens is a contribution to the development of immunotherapeutic approaches to treat cancer. Recent reports have shown the expansion and differentiation of CD34 + progenitor cells into mature DCs. [1] [2] [3] [4] [24] [25] [26] Here, we describe an optimized expansion and transduction protocol for CD34
+ cord blood cells utilizing VSV-G pseudotyped retroviral particles. It allows the rapid expansion of cord blood derived CD34
+ progenitor cells by an average factor of 160 (Figure 1 ). Exponentially growing cells were efficiently transduced with a gene for the tumor-associated antigen tyrosinase and the reporter gene EGFP-ZEO R , utilizing a transduction protocol without the use of methylcellulose or fibronectin fragments. 3, 4 A common problem observed with MoMuLV vectors has been the silencing of transgene expression over time. A previous report described a complete silencing of MoMuLV proviral sequences in a mouse model within 6 weeks. 27 Silencing of proviral sequences could be due to de novo methylation of proviral sequences and altered histone acetylation status over time. 28, 29 Another report described a methylase-independent mechanism of proviral silencing through MoMuLV and immunodeficiency virus type 1 (HIV-1) cis-acting sequences. 30 Facing this problem we decided to transduce the CD34 + progenitor cells with titers ranging from 100 to 150 MOI, which resulted in a high tyrosinase mRNA and concomitant EGFP expression in the first 3 days after transduction. Nevertheless, we revealed a strong silencing of transgenes in the cells during the expansion phase of the progenitor cells. We observed that the mean of fluorescence intensity of EGFP-positive cells remained stable, whereas the percentage of EGFP-positive cells in the culture was decreased. We suggest that this observed effect could be due to decreased proliferation of cells transduced with the VSV-G pseudotyped retroviral particle compared with non-transduced cells. It also might be that a strong retroviral silencing or dilution of unintegrated proviral copies appeared during the coupled. We suggest that high levels of stable EGFP protein caused this discrepancy. Recently, it has been shown that the extended half-life of EGFP protein can mask an inhibition of proviral transcriptional expression in DCs. 31 However, tyrosinase protein expression could be detected 24 days after transduction using our 9A1 monoclonal antibody, suggesting that the diminished mRNA copy number is efficiently translated in tyrosinase protein. Furthermore, the tyrosinase expression in differentiated DCs was capable of inducing a cytotoxic response of the tyrosinase-peptide specific T-cell clone TyrF8. 23 We conclude that the silencing of provirus sequences occurs during expansion of hematopoietic progenitor cells and that this might be overridden by the high copy number of proviral sequences and the subsequent differentiation in dendritic cells. Multiple proviral integrations in the genome of the host bear the risk of activating protooncogenes and therefore the risk of transformation. Recently, such a transformation has been described in a mouse system by introducing the clinically used dLNGFR marker gene into mouse hematopoietic stem cells. 32 Here, the integration of a provirus in the murine gene Evi1 led to acute myeloid leukemia. However, the effect observed in this study was probably due to a cooperative effect of overexpressed Evi1 and the remaining biological activity of the dLNGFR marker gene, because activation of Evi1 alone was not sufficient to induce AML in mice. 32 Furthermore, a recent report showed that transduction of mouse hematopoietic stem cells with highly concentrated HIV vectors led to a stable expression of a therapeutic globin gene in transplanted mice without the development of hematopoietic malignancies. 33 In the human system, the transduction of human progenitor cells with VSV-G pseudotyped HIV vectors at 60 to 300 MOI also did not result in hematopoietic disorders in transplanted NOD/SCID mice. 34 In line with the latter reports, our experiments showed that the high MOI used for the transduction of human CD34 + cells did not lead to transformed cells or a decrease in cell viability. Nevertheless in the future, non-silenced vectors must be created to minimize the negative positional effects, which may arise from multiple integrations in the genome of the host cell.
Further analysis revealed that transduced CD34 + cells which were differentiated into dendritic cells could efficiently process and present the tumor-associated antigen tyrosinase resulting in activation of a tyrosinase peptide-specific T cell clone ( Figure 7 ). Thus vaccination with CD34 + -derived dendritic cells genetically engineered to express tumor-associated antigens may be a useful tool in eliciting a therapeutic T cell response against tumors. In summary, we have provided evidence that a high MOI for transduction of CD34
+ progenitor cells and subsequent differentiation into functional dendritic cells can lead to a long-term expression of the transgene. The use of the bicistronic vector described in this report will allow further dominant selection of cells expressing the transgenes which can be implemented in an in vitro expansion and selection protocol for clinical applications.
Materials and methods
Preparation and cultivation of human CD34
+ umbilical cord blood cells Cord blood preparations were obtained from the stem cell laboratory, Department of Internal Medicine I, Medi-Gene Therapy cal Faculty Dresden, Technical University Dresden, with informed consent of the blood donors. Briefly, HLA-A * 0201 PBMCs were separated by Ficoll-Hyaque (Biochrom AG, Berlin, Germany) density centrifugation and CD34-positive cells were isolated by immunomagnetic cell purification using the direct CD34-Progenitor kit (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the instructions of the supplier. About 5 × 10 5 to 2 × 10 6 CD34-positive cells could be isolated from 100 ml to 200 ml of cord blood samples. FACS analysis using an anti-human CD34 phycoerythrin-coupled antibody (Clone 5B1, Miltenyi Biotech) revealed that 95-99% of the cells showed surface expression of the CD34 molecule. Cells were expanded in RPMI1640 medium (GIBCO BRL, Eggenstein, Germany) supplemented with 2 mM L-glutamine, 1% nonessential amino acids (Biochrom AG), 100 U/ml penicillin, 100 g/ml streptomycin (both from Gibco BRL), 5 × 10 Ϫ5 M 2-mercaptoethanol and 10% heat-inactivated fetal calf serum (Gibco BRL) which is referred to as stem cell medium (SCM). Before use the medium was supplemented with granulocyte macrophage colony-stimulating factor (GM-CSF, 200 U/ml), tumor necrosis factor-alpha (TNF-␣, 0.5 ng/ml), fms-like tyrosine kinase 3-ligand (flt-3-L, 20 ng/ml), and stem cell factor (SCF, 20 ng/ml) (all cytokines were provided by Strathmann Biotech, Hannover, Germany). The proliferation of the CD34 + -derived cells was monitored every day concomitantly adding fresh SCM supplemented with cytokines to obtain 5 × 10 5 cells/ml during the whole expansion phase. At day 5 to 7 the cells exhibited strong proliferation and were used for transduction with retroviral vectors.
Generation of anti-tyrosinase monoclonal antibody and staining of tyrosinase expressing CD34
+ cells The cDNA of human tyrosinase was kindly provided by Dr T Wolfel (Medical Department III, Johannes-Gutenberg-University Mainz, Mainz, Germany) and the cDNA coding for a 28 kDa intramelanosomal domain (aa 285-475), containing the peptide sequence YMDGTMSQV, was modified by PCR using the primers TyrN2 (5'-CACGGATCCCATCAGTCTTTATGCAATGGA) and TyrC1 (5'-AACTGCAGGTGATGGTGATGGTGATGCC AGATCCGACTCGCTTGTT) resulting in additional 5Ј-BamHI and 3Ј-PstI restriction sites, respectively. The PCR product was ligated into pGEM-T (Promega, Mannheim, Germany) and the sequence of the human tyrosinase was verified by sequencing using the pUC M13 reverse and forward primer. The BamHI/PstI fragment containing the human tyrosinase was excised and ligated into the expression vector pQE30 (Qiagen, Hilden, Germany) using the the appropriate BamHI and PstI sites of the vector enabling expression with N-terminal 6xHis-tag.
The recombinant tyrosinase fragment was overexpressed in E. coli M15[pREP4] (Qiagen), purified from cell lysates by affinity chromatography on Ni-NTA-agarose column and refolded by dialysis against buffer RFB (100 mM H 3 BO 3 , 10 mM Tris, pH 7.4).
Refolded tyrosinase was used to immunize BALB/c mice (1 × 100 g and 3 × 50 mg). Hybridomas were generated by the fusion of spleen cells with X-63AG8 myeloma cells according to standard procedures. Hybridomas were screened for reactivity with recombinant tyrosinase fragment by ELISA and Western blotting. One of the tyrosinase mAb (9A1) recognizing recombinant human tyrosinase as well as intracellular tyrosinase, was used for the detection of tyrosinase in transduced cells and on Gene Therapy slices of melanoma biopsies. Detection of tyrosinase on paraffin-embedded histopathologically confirmed melanoma biopsies was performed with the 9A1 antibody (1:120) and secondary staining with alkaline phosphatase coupled secondary goat anti-mouse antibody, using the DAKO ChemMate Detection Kit (DAKO, Hamburg, Germany) according to the instructions of the supplier. For the detection of tyrosinase in DCs, PFA-fixed cytospins of transduced and non-transduced CD34 + -derived DCs were washed three times with PBS/0.1% BSA and incubated with the 9A1 antibody (1:80 diluted) for 1 h in a humidified chamber. After washing with PBS/0.1% BSA, the cells were incubated for 1 h with peroxidase conjugated anti-mouse IgG (stock solution, diluted 1:80, as recommended by the supplier, DAKO, Hamburg, Germany). Cytospins were washed three times in PBS/0.1% BSA, and incubated for 10 min with H 2 O 2 and 3-amino-9-ethyl-carbazole (Sigma, Dreieich, Germany). The enzymatic reaction was stopped with doubledistilled water, and the cells were counterstained with MayerЈs hemalaun before being examined by microscopy.
Retroviral vectors and generation of VSV-G pseudotyped particles
The full length cDNA of the human tyrosinase in QE30 (Qiagen) was excised with EcoRI and HindIII and subcloned into the corresponding restriction sites of pBK-CMV (Stratagene, Amsterdam, The Netherlands) to obtain an additional 3Ј-SmaI restrictions site. The full length tyrosinase cDNA was excised by EcoRI/SmaI digestion and the 1.6 kb restriction fragment was ligated into the EcoRI/SwaI restriction sites of the Moloney murine leukaemia virus derived vector pcz-CFG5-IEGZ. (This vector originally described as pEGZ/MCS has been renamed by Dirk Lindemann (Institute of Virology, Medical Faculty Carl Gustav Carus, Technical University Dresden, Dresden, Germany) as pcz-CFG5-IEGZ. 35, 36 ) resulting in the vector pcz-CFG5-Tyr-IEGZ. The tyrosinase sequence and the vector insert boundaries were verified by sequencing using both strands using the ALFexpress Auto Read sequencing kit (Amersham Pharmacia Biotech) with cyanine-labeled forward primer CFG2/5-5.1 5Ј-GACCACCCCCACCGCCCTC and reverse primer CFG2/5-3.1 5Ј-GCCAAACCTACAGGTGGGG. To validate the bicistronic expression of tyrosinase and EGFPZeo R we generated pt67 cells (Clontech, Heidelberg, Germany) permanently expressing pcz-CFG5-Tyr-IEGZ (pT67-Tyr-IEGZ) and pcz-CFG5-IEGZ (pT67-IEGZ), respectively. These cell lines were used to analyze the expression of the transgenes by confocal laser scan microscopy (Leica TCS-NT, Heidelberg, Germany). Tyrosinase protein was detected with the monoclonal antibody 9A1 and a secondary goat anti-mouse IgG phycoerythrin-coupled antibody (1:120 diluted stock solution, DAKO).
Recombinant retroviral particles were generated by using the three vector packaging system as described. Briefly, 293T cells were transiently cotransfected with an expression construct for gag-pol (pHIT60), the MoMuLVbased retroviral vectors and the vesicular stomatitis virus G-protein (pcz-VSV-Gwt, described previously. [35] [36] [37] [38] The transfected 293T cells were cultured in stem cell medium without cytokines until virus supernatants were harvested 48 to 72 h after transfection. Twenty-four hours after transfection, fresh medium containing 10 mM sodium butyrate was added to enhance expression of the retroviral vector. Virus supernatants were pooled and filtered (0.45 m pore size filter), polybrene (Sigma) was added to a final concentration of 8 g/ml, and the supernatants were either used immediately or stored at Ϫ80°C. The retroviral titer (infectious units, IU) was determined by plating 10 5 HeLa target cells in 30-mm wells and transducing with diluted 1:10 to 1:10 7 viral supernatants. To detect replication competent viruses supernatants from the transduced HeLa, cells were used to infect proliferating HeLa cells. No replication competent viruses were detected in any of the vector preparations.
Transduction of primary human cord blood CD34
+ cells The day before transduction 1 × 10 5 CD34 + progenitor cells per well in a 24-well plate were fed with fresh stem cell medium containing recombinant human cytokines (200 U/ml GM-CSF, 0.5 ng/ml TNF-␣, 50 ng/ml IL-3 and 500 U/ml IL-6, all cytokines were from Strathmann Biotech, Hannover, Germany). The next day, cells were incubated with supernatants containing VSV-G pseudotyped pcz-CFG-5-IEGZ or pcz-CFG5-Tyr-IEGZ retroviral particles supplemented with cytokines and centrifuged at 2400 g, 30°C for 2 h. The cells were transduced with retroviral titers ranging from 100 to 150 MOIs. Seventy-two hours after transduction, cells expressing the EGFP reporter were determined by FACS analysis. After 16 h in culture, the transduction step was repeated and cells were cultivated in stem cell medium containing 200 U/ml GM-CSF and 0.5 ng/ml TNF-␣. The cell viability thereafter was greater than 97% as determined with trypan blue exclusion. The cells differentiated into dendritic cells by increasing the concentration of TNF-␣ to 50 ng/ml. One day before the tyrosinase-specific CTL assay, the non-transduced and transduced cells were incubated with CD40L (Strathmann Biotech) and LPS (E. coli 026:B6, Sigma) to enhance antigen presentation as described. 39 
Southern blot and hybridization
To analyze the proviral copy number, transductions of CD34 + cells were performed at 100 MOI. After determination of the transduction efficacies by FACS-assisted quantification of EGFP-positive cells, the genomic DNA was prepared 12 days after transduction from non-transduced and pcz-CFG5-Tyr-IEGZ-tranduced cord blood CD34 + cells from the same donor using the QIAampBlood Mini kit (Qiagen). 10 g of DNA was digested overnight with SacI/EcoRI, releasing an internal proviral 3.7 kb fragment containing the complete tyrosinase coding region and a genomic 2.3 kb fragment containing tyrosinase exon 1, representing two copies of the gene. As a positive control we included 1 × 10 Ϫ9 and 1 × 10 Ϫ10 g pcz-CFG5-Tyr-IEGZ vector digested with EcoRI/SacI. The digests were subjected to a 0.6% agarose gel electrophoresis. Denaturated DNA was blotted on to Hybond N filters and hybridized with a ␣-32 P-dCTP (Amersham Pharmacia Biotech, Freiburg, Germany) random primed labbeled DNA probe complemetary to 501 bp of tyrosinase exon 1 according to a standard protocol. 40 After washing with 0.5 SSC/0.1 SDS at 58°C, the filter was placed into a phospo-imager cassette. After 3 and 10 days' exposure, quantification of absolute proviral copy number was performed by densitometric analysis of bands representing proviral DNA compared with the genomic tyrosinase gene using the Phospho Image Scanner PhosphoImager SI (Molecular Dynamics, Amersham Pharmacia Biotech) and the ImageQuant v5.1 program. Relative proviral copy number (proviral copy number in EGFP-positive cells) was calculated by adjusting the absolute proviral copy number to the EGFP-positive cells.
RNA isolation and RT-PCR
Total RNA was prepared from non-transduced and transduced CD34
+ -derived DCs 24 days after transduction using the TriPure isolation reagent-kit (Roche, Mannheim, Germany) as recommended by the supplier. RNA also was prepared from HeLa cells transfected with the vector pcz-CFG5-Tyr-IEGZ to serve as a positive control. The reverse transcription and generation of cDNA was accomplished with the Advantage RT-for PCR-kit (Clontech, Heidelberg, Germany) according to the supplier's instructions. The tyrosinase coded by the retrovirus was detected as a 550 bp fragment, using a primer that was complementary to sequences in exon 2 and exon 5, respectively, of the tyrosinase gene published by Brichard et al 7 (oligonucleotide sequences: TyrN1: 5Ј-CAC-CATCAGTCTTTATGCAATGGA and TyrC1: 5Ј-AACCA GATCCGACTCGCTTGTT). The PCR was performed in a final volume of 25 l (2.5 mM MgCl 2 , 1 × PCR buffer, 0.4 mM dGTP, dATP, dCTP, dTTP, 10 M of each of the two DNA primers, 1 U Taq DNA polymerase (Amersham, Pharmacia Biotech). PCR samples were first denatured at 95°C for 5 min, followed by 35 cycles (95°C 1 min; 60°C 1 min; 72°C 2 min) and a final extension at 72°C for 5 min in a thermal cycler (UNO II, Biometra, Goettingen, Germany).
Real-time PCR
To analyze the expression of tyrosinase in transduced CD34
+ cells and derived dendritic cells over time, total RNA from pcz-CFG5-Tyr-IEGZ-transduced cells was isolated at day 3, 8, 15 and 25 post transduction and its concentration was determined photometrically. First-strand cDNA was synthesized with the Advantage RT for PCR kit (Clontech) using 1 g of total RNA (DNase-treated) and oligo dT-primers according to the supplier's instructions. For standard calibration, the vector pcz-CFG5-Tyr-IEGZ was used at serial 10-fold dilutions representing 1 to 10 7 molecules/ml pcz-CFG5-Tyr-IEGZ in the PCR capillary (Roche). The primers RealTYR-forward (5Ј-GGCTGTTTTGTACTGCCTGC) and RealTYR-reverse (5Ј-GTGAAGGGAAATTGAGGCCC) were synthesized according to the published tyrosinase sequence. 8 They were used to amplify a 207 bp region of tyrosinase exon 1. All real-time PCR reactions were performed in a 20 l reaction mixture containing 0.1 g reverse-transcribed RNA, 5 pmol of each primer and LightCycler-DNA Master SYBR Green I (Roche) in the Light Cycler Instrument (Roche). Quantification of the tyrosinase transcript, isolated at different time-points after transduction, was performed with the second derivative maximum method using an external standard curve. 22 The fluorescence threshold calculation and the real-time quantitations were performed using the LightCycler Software 3 (Roche).
Chromium release assay
The ability of CD34 + -derived DCs to present an intracellular-produced tryosinase-derived peptide after trans-duction with pcz-CFG5-Tyr-IEGZ or with the control vec
